41 completed, 10 terminated, 6 recruiting, 5 withdrawn. 70 Phase 1, 30 Phase 2.
Follow plerixafor: new trials by email Literature Review of plerixafor trials Research Report on plerixafor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Stem Cell Mobilization and Apheresis for Life-threatening Blood Disorders Filgrastim, Plerixafor, Leukapheresis - Bone Marrow Failure Syndrome | Phase 1 | Recruiting | St. Jude Children's Research Hospital | 12 | 2026-11-01 | 2026-10-06 |
| Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIM Busulfan, Palifermin, Plerixafor - WHIM, Warts | Phase 1 / Phase 2 | Enrolling by invitation | National Institute of Allergy and Infectious Diseases (NIAID) | 10 | 2026-10-21 | 2026-10-27 |
| Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy Plerixafor, Filgrastim, Palifermin - X-linked Severe Combined Immunodeficiency, X-SCID | Phase 1 / Phase 2 | Enrolling by invitation | National Institute of Allergy and Infectious Diseases (NIAID) | 18 | 2025-05-09 | 2026-10-13 |
| Gene Editing For Sickle Cell Disease Plerixafor, Busulfan, Gene-modified CD34+ cells - Sickle Cell Disease | Phase 1 | Recruiting | St. Jude Children's Research Hospital | 25 | 2025-03-21 | 2026-10-15 |
| Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML Rabbit Anti thymocyte globulin, Busulfan, Fludarabine - AML, Childhood, Aml | Phase 1 / Phase 2 | Recruiting | Washington University School of Medicine | 68 | 2024-11-15 | 2026-08-24 |
| Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder G-CSF (filgrastim or biosimilar), Apheresis, Plerixafor - RUNX1 Familial Platelet Disorder | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 4 | 2024-05-20 | 2026-06-11 |
| Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease Campath, Sirolimus, Base-edited hematopoietic stem and progenitor cells - Chronic Granulomatous Disease (CGD), X-Linked Chronic Granulomatous Disease | Phase 1 / Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 15 | 2024-04-17 | 2026-08-13 |
| Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ... RIC, GVHD prophylaxis, allo HCT - HIV, Hematologic Malignancies | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 265 | 2023-01-26 | 2026-10-16 |
| A Dose Finding Study of CycloSam® Combined With External Beam Radiotherapy 153Sm-DOTMP, External beam radiotherapy., Calcium Carbonate - Osteosarcoma, Bone Metastases | Phase 1 | Withdrawn | Albert Einstein College of Medicine | 2022-08-01 | 2022-10-14 | |
| Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia TBI, Hydroxyurea, briquilimab - Sickle Cell Anemia, Beta Thalassemia | Phase 1 / Phase 2 | Active not recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 40 | 2022-05-12 | 2026-03-12 |
| Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft Purified regulatory T-cells (Treg) plus CD34+ HSPC, Fludarabine, Melphalan - Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies | Phase 1 | Active not recruiting | Stanford University | 66 | 2021-09-07 | 2026-05-12 |
| Study Assessing Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MGTA-145 in Healthy Volunteers as a Single Agent or in Combination With Plerixafor MGTA-145, plerixafor, Placebo - Healthy Volunteers | Phase 1 | Completed | Ensoma | 107 | 2019-04-22 | 2024-01-11 |
| A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease Plerixafor, Busulfan, BIVV003 - Sickle Cell Disease | Phase 1 / Phase 2 | Completed | Sangamo Therapeutics | 7 | 2019-03-06 | 2025-09-12 |
| Safety of Blood Stem Cell Mobilization With Plerixafor in Patients With Sickle Cell Disease Plerixafor - Sickle Cell Disease | Phase 1 | Active not recruiting | City of Hope Medical Center | 5 | 2018-09-19 | 2026-09-02 |
| TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma 18F-FHBG, Aldesleukin, Cellular Therapy - HLA-A*0201 Positive Cells Present, NY-ESO-1 Positive Tumor Cells Present | Phase 1 | Withdrawn | Jonsson Comprehensive Cancer Center | 2018-07-10 | 2020-07-24 | |
| Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM) Plerixafor, Alemtuzumab, Anakinra - Diabetes Mellitus, Type 1 | Phase 1 / Phase 2 | Completed | University of Alberta | 22 | 2017-08-15 | 2024-07-19 |
| Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer 18F-FHBG, Aldesleukin, Busulfan - HLA-A*0201 Positive Cells Present, Locally Advanced Malignant Neoplasm | Phase 1 | Terminated | Jonsson Comprehensive Cancer Center | 5 | 2017-07-26 | 2023-11-01 |
| Peripheral Blood Stem Cell Collection for Sickle Cell Disease (SCD) Patients Plerixafor - Sickle Cell Disease | Phase 1 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 15 | 2017-07-25 | 2023-09-21 |
| To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas Plerixafor - Pancreas Cancer | Phase 1 | Terminated | Weill Medical College of Cornell University | 2 | 2017-07-25 | 2020-03-02 |
| Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and Plerixafor G-CSF, Plerixafor - Fanconi Anemia | Phase 1 / Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 4 | 2017-02-10 | 2025-09-11 |
Showing 20 of 70. Sign in to see all of them.
Leukemia, Myeloid, Acute (17) · Anemia, Sickle Cell (7) · Myelodysplastic Syndromes (7) · Leukemia (6) · Lymphoma, Non-Hodgkin (5) · Multiple Myeloma (5) · Fanconi Anemia (4) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Hodgkin Disease (3) · Recurrence (3) · Agammaglobulinemia (2) · Glioblastoma (2) · Gliosarcoma (2)
Washington University School of Medicine (10) · Genzyme, a Sanofi Company (6) · M.D. Anderson Cancer Center (4) · National Institute of Allergy and Infectious Diseases (NIAID) (4) · City of Hope Medical Center (3) · Fred Hutchinson Cancer Center (3) · National Heart, Lung, and Blood Institute (NHLBI) (3) · St. Jude Children's Research Hospital (3) · Assistance Publique - Hôpitaux de Paris (2) · Jonsson Comprehensive Cancer Center (2) · Weill Medical College of Cornell University (2) · Albert Einstein College of Medicine (1) · Alessandra Biffi (1) · CCTU- Cancer Theme (1) · Cardiff University (1)
United States (61) · United Kingdom (4) · France (3) · Spain (3) · Canada (2) · Belgium (1) · Czechia (1) · Denmark (1) · Germany (1) · Hungary (1) · Israel (1) · Italy (1) · Netherlands (1) · Poland (1)
Suk S De Ravin, M.D. (3) · Geoffrey Uy, M.D. (2) · Hans-Peter Kiem (2) · John F Tisdale, M.D. (2) · Mark Schroeder, M.D. (2) · Akshay Sharma, MBBS, MSc (1) · Alan K Burnett (1) · Alessandra Biffi, MD (1) · Alexis Leonard, MD (1) · Amanda F. Cashen, M.D. (1) · Amrita Krishnan (1) · Andreas K Klein, MD (1) · Ashok Srinivasan, MD (1) · Baburao Koneru, MD (1)
PMID 21835955, PMID 21890643, PMID 22308295, PMID 24523241, PMID 24723677, PMID 25105369, PMID 27118452, PMID 27535663, PMID 27846612, PMID 28292947, PMID 28718760, PMID 29392425, PMID 29419425, PMID 29472357, PMID 29724902, PMID 31352850, PMID 31456261, PMID 31501599, PMID 31940591, PMID 32127657, PMID 33956057, PMID 34160085, PMID 34166998, PMID 34175041, PMID 34398557, PMID 34515338, PMID 34751952, PMID 36163427, PMID 39413163, PMID 39642902, PMID 40330596, PMID 40593578
2014 (3), P30CA015704 (1), P30CA033572 (1), P30CA124435 (1), P50CA107399 (1), R01CA163870 (1), R01HL081499 (1), R01HL116217 (1), R21CA143805 (1), U01HL163983 (1)